BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
TZID:Asia/Dubai
BEGIN:STANDARD
TZOFFSETFROM:+0400
TZOFFSETTO:+0400
TZNAME:+04
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250107T200000
DTEND;TZID=America/Los_Angeles:20250107T210000
DTSTAMP:20260412T152755
CREATED:20241210T144604Z
LAST-MODIFIED:20250312T142843Z
UID:1703-1736280000-1736283600@clinicaltmssociety.org
SUMMARY:Grand Rounds Webinar: "Oops\, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Oops\, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse. \nSpeaker: Colleen A. Hanlon\, PhD\nJoin us for an insightful session on Transcranial Magnetic Stimulation (TMS) as an innovative treatment for addiction. This session will explore the FDA approved use of TMS for smoking cessation\, European clearance for stimulant use disorder\, and emerging evidence supporting its application in alcohol use disorders. Learn about the mechanisms of action\, current clinical research\, and practical strategies for integrating TMS into your addiction treatment protocols. Designed for physicians and mental health providers\, this session will provide valuable insights into how TMS can enhance patient outcomes and expand treatment options for substance use disorders. \nAt the end of the presentation\, attendees will:\n- Identify the current FDA indication for TMS in smoking cessation and discuss the emerging evidence supporting its use in stimulant and alcohol use disorders.\n- Describe the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.\n- Evaluate the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use. \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, January 10\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nOne hour CME credit is available - Click here for CE Language \nWhen:\nUSA - January 7\, 2025 at 8:00pm EST | 5:00pm PST\nUK- January 8\, 2025 at 1:00am GMT\nAustralia- January 8\, 2025 at 12:00pm AEDT \nCost:\nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \nAll Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event. \n> >Register Now <<\nAbout the Speaker: Colleen A. Hanlon\, PhD\n \nVice President\, Medical Affairs\, BrainsWay\nProfessor (adjunct)\, Wake Forest University School of Medicine \nDr. Hanlon is an internationally recognized thought-leader in the development and expansion of non-invasive neuromodulation therapeutics for new populations. \nShe is currently serving as the Vice President of Medical Affairs for BrainsWay and Director of their Innovation Team. Before coming to BrainsWay she was a tenured professor at the Wake Forest School of Medicine. There she ran a multidisciplinary research program devoted to developing brain-circuit based interventions for individuals struggling with drug and alcohol use disorders. She has nearly 20 years of clinical research experience in transcranial magnetic stimulation (TMS) and brain imaging. Recognized as a pioneer int TMS for addiction\, Dr. Hanlon received over $12 million in National Institute of Health funding\, led over 15 clinical studies of TMS\, published over 100 peer-reviewed publications\, and mentored over 75 trainees in brain imaging and TMS. \nShe received her undergraduate degree from the University of Florida\, a Ph.D. in neurobiology from Duke University wherein she focused on motor recovery after stroke and in Parkinsons Disease using functional MRI. She did a postdoctoral fellowship at Wake Forest University wherein she first became interested in neuromodulation. \nIn 2023\, she was given the prestigious International Brain Stimulation Early Career Investigator award and she is the senior author on the first “Consensus Paper” published by a group of over 70 scientists from over 10 countries outlining the path forward for Non-Invasive Therapeutic Development for Addiction. \nIn addition to advancing the science and evidence for TMS for various indications\, she also participates in the research training and education community at local\, national\, and international levels. She has directed the Advanced TMS Training Course sponsored by the National Center for Neuromodulation for Rehabilitation and has served on the grassroots Advocacy committee and Public Policy committees of several scientific organizations devoted to expanding access to care for individuals with drug and alcohol use disorders. \n  \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/tms-to-promote-sobriety/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/12/Grand-Rounds-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250204T080000
DTEND;TZID=America/New_York:20250204T200000
DTSTAMP:20260412T152755
CREATED:20250113T160420Z
LAST-MODIFIED:20250312T142724Z
UID:1933-1738656000-1738699200@clinicaltmssociety.org
SUMMARY:Grand Rounds Webinar: Recent Advances in Neurotherapeutics for Child and Adolescent Mood Disorders
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Recent Advances in Neurotherapeutics for Child and Adolescent\nMood Disorders" \nSpeaker: Paul E. Croarkin\, DO\, MS\nJoin Dr. Croarkin for an update on the clinical implementation and research of transcranial magnetic stimulation for adolescents with depression. Dr. Croarkin will also review recent\, ongoing\, and planned research focused on neurotherapeutics. \nAt the end of the presentation\, attendees will:\n\nDemonstrate a working knowledge of noninvasive brain stimulation modalities such as transcranial electrical stimulation\, transcranial magnetic stimulation\, and electroconvulsive therapy.\nDemonstrate the ability to discuss recent studies adapting transcranial magnetic stimulation for adolescents with major depressive disorder.\nDemonstrate the ability to discuss recent research with ketamine in adolescents and to discuss potential future studies and related challenges with psychedelic therapeutic.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, Friday\, February 7\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nOne hour CME credit is available - Click here for CE Language \nWhen:\nUSA - February 4\, 2025 at 8:00pm EST | 5:00pm PST \nUK- February 5\, 2025 at 1:00am\nGMT \nAustralia- February 5\, 2025 at\n12:00pm AEDT \nCost:\nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \nAll Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event. \n> >Register Now <<\nAbout the Speaker: Paul Croarkin\, DO\, MS\n \nDr. Croarkin is the Ervin A. and Margaret C. Mueller Director of the Children’s Research Center at Mayo Clinic and the Chair for Pediatric\nResearch in the Department of Pediatrics and Adolescent Medicine. He is a professor of Psychiatry\, Pediatrics\, and Pharmacology in the Mayo Clinic College of Medicine and Science. He serves as the Editor-in-Chief for the Journal of Child and Adolescent Psychopharmacloogy. \nDr. Croarkin completed medical school at the University of North Texas Health Science Center. He then completed residency training in psychiatry at Naval Medical Center San Diego\, where he served as chief resident. Following this\, Dr. Croarkin served as a US Navy psychiatrist in an academic role at Walter Reed Army Medical Center and in an operational setting as a psychiatrist embedded with the 24th Marine Expeditionary Unit in North Babil during Operation Iraqi Freedom. He returned for clinical and research training in child\nand adolescent psychiatry at UT Southwestern Medical Center in Dallas\, again serving as chief resident. He earned a Master of Science degree with distinction in clinical science from the Graduate School of Biomedical Sciences at UT Southwestern Medical Center. Thereafter\, he joined the Mayo Clinic Department of Psychiatry and Psychology. \nAn expert in child\, adolescent\, and adult mood disorders\, neurotherapeutics\, and psychopharmacology\, Dr. Croarkin conducts research to develop innovative diagnostic and treatment approaches for children and adolescents. His research has been funded by the National Alliance for Research on Schizophrenia and Depression\, the National Institutes of Health\, and industry partnerships. His team focuses on adapting and innovating neurotherapeutics for youth with psychiatric disorders while studying GABAergic and glutamatergic\nneurotransmission. These efforts have informed and supported the clinical implementation of transcranial magnetic stimulation interventions for adolescents with depression. His findings have been published in numerous peer-reviewed journals\, including The Journal of the American Academy Child and Adolescent Psychiatry\, JAMA Psychiatry\, and Neuropsychopharmacology. \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/advances-in-neurotherapeutics-for-children/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/01/Grand-Rounds-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250304T200000
DTEND;TZID=America/New_York:20250304T210000
DTSTAMP:20260412T152755
CREATED:20250213T221023Z
LAST-MODIFIED:20250312T142138Z
UID:2078-1741118400-1741122000@clinicaltmssociety.org
SUMMARY:Practical Ethics for TMS Practices
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Practical Ethics for TMS Practices" \nSpeaker: Ian Cook\, MD\, DLFAPA\, FCTMSS\nEthical issues arise every day when providing TMS therapy\, whether around professionalism\, boundaries\, transparency\, or conflicts of interest. Interactions with patients\, manufacturers\, colleagues\, and the public may challenge us and members of our care teams. Fortunately\, there are frameworks that can help us identify the issues and guide our approaches so we can uphold professional standards. \nUsing illustrative case vignettes\, in this webinar we'll explore the ethical challenges in TMS practice with Dr. Ian Cook\, long-time co-chair of the CTMSS Legal\, Business\, and Ethics Committee\, and a Member of our Board. \nDuring this presentation\, attendees will address these three key topic areas: \n\nProfessionalism\nBoundaries\nTransparency and Conflicts of Interest\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available. \nCE Language \n*Registered attendees will receive access to the on-demand video recording by Friday\, Friday\, March 7\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen:\nUSA - March 4\, 2025 at 8:00pm EST | 5:00pm PST\nUK- March 5\, 2025 at 1:00am GMT\nAustralia- March 5\, 2025 at 12:00pm AEDT \nCost: Members: $25 | Non-members $50 | Trainee Members FREE \n> >Register Now <<\nIan Cook\, MD\, DLFAPA\, FCTMSS\n \nDr. Ian A. Cook is the founding Director and CEO of the Los Angeles TMS Institute and a Professor Emeritus of Psychiatry and of Bioengineering at UCLA. His career has largely focused on improving the treatment of mental illnesses by working at the interface between medicine and technology. \nIn his 25+ year academic career at UCLA\, he started the Unipolar Depression Research and Clinic Program\, held an endowed chair in Depression Research\, treated the first patient in his UCLA TMS Treatment Service in March 2009\, and served as a member of the rTMS Task Group of the National Network of Depression Centers. He was Chief of Staff at UCLA’s Neuropsychiatric Hospital and was elected Chair of the Faculty of the David Geffen School of Medicine. He also was appointed Chief Translational Innovation Officer for the Semel Institute for Neuroscience and Human Behavior. \nFor many years he was a member of the Executive Committee on Practice Guidelines of the American Psychiatric Association\, helping guide their dissemination of evidence-based practices in psychiatry. Nationally\, he also served as a standing member of the NIH’s ITVA Review Committee (“Interventions Committee for Adult Disorders”). \nHe left UCLA in 2018 to start the Los Angeles TMS Institute and bring advanced treatment modalities out of the laboratory and into clinical care in Southern California. \nDr. Cook received his undergraduate degree in engineering from Princeton University and graduated from the Yale School of Medicine before coming to UCLA for his residency training. He then completed an NIMH T32 Research Fellowship before joining the UCLA faculty. \nHe is a Distinguished Life Fellow of the American Psychiatric Association and one of the inaugural Fellows of the Clinical TMS Society. He joined the Board of the Society in 2013\, has been co-chair of its Legal\, Business\, and Ethics Committee for many years\, and received the President’s Award in 2021. He is Vice President and a founding Board Member of the Foundation for the Advancement of Clinical TMS. \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/practical-ethics-for-tms-practices/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/02/Grand-Rounds.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250307
DTEND;VALUE=DATE:20250310
DTSTAMP:20260412T152755
CREATED:20241209T173730Z
LAST-MODIFIED:20250304T210416Z
UID:1678-1741305600-1741564799@clinicaltmssociety.org
SUMMARY:Pulses - Orlando
DESCRIPTION:This in-depth training course offers a certificate of completion and features lectures and over 2 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers and some special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best evidence. \nRegister Now\n  \nDate/Time: Friday March 7\, 2025 (4pm ET) - Sunday\, March 9\, 2025 (3pm ET) (time is subject to change) \nLocation: The Omni Orlando Resort at ChampionsGate: 1500 Masters Blvd\, ChampionsGate\, FL 33896 \nThe program includes: \n1. An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker\, who designed the first-ever TMS machine in 1985;\n2. A review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies;\n3. Four lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management;\n4. A review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, maintenance treatment;\n5. A revised lecture on TMS risk and their prevention and management\, including seizure protocol review;\n6. Hands-on training on coil location placement & motor threshold determination with multiple TMS devices;\n7. A review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain; and An extended Q & A Panel with all PULSES faculty and special guests.\n8. After completion of the course\, the clinician will have obtained a historical\, current\, and practical knowledge of the scientific basis for treating psychiatric patients with TMS. \nAttendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion. \nCancellation Policy: \nConference registration cancellations must be received in writing on or before February 1\, 2025\, to receive a refund minus a $100.00 administration fee.\nConference registration may not be transfered to a future conference.\nNo refunds will be issued for cancellations received after February 1\, 2025.\nIn the event CTMSS must cancel the conference due to unforeseen circumstances\, CTMSS will refund the cost of registration. However\, CTMSS does not assume responsibility for any additional costs\, charges\, or expenses; to include\, charges made for travel and lodging
URL:https://clinicaltmssociety.org/event/pulses-orlando/
LOCATION:Omni Orlando Resort at ChampionsGate\, 1500 Masters Blvd\, Championsgate\, FL\, United States
CATEGORIES:All Events,PULSES
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/12/2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250325T200000
DTEND;TZID=America/New_York:20250325T210000
DTSTAMP:20260412T152755
CREATED:20250312T005902Z
LAST-MODIFIED:20250312T005902Z
UID:2175-1742932800-1742936400@clinicaltmssociety.org
SUMMARY:Minding Your Own TMS Business
DESCRIPTION:📅 March 25\, 2025 \n📍 Virtual  \nModerated by Dr. Linda Carpenter\, with an all-female panel\, including current CTMSS President\, Dr. Martha Koo\, Dr. Rebecca Allen\, Dr. Carlene MacMillan and Dr. Kristin Raj.   \n$25 Donation. All proceeds benefit the Patient Assistance Fund.  \nREGISTER NOW >
URL:https://clinicaltmssociety.org/event/minding-your-own-tms-business/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/03/FACTMS-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250506T200000
DTEND;TZID=America/New_York:20250506T210000
DTSTAMP:20260412T152755
CREATED:20250402T163454Z
LAST-MODIFIED:20250610T174022Z
UID:2262-1746561600-1746565200@clinicaltmssociety.org
SUMMARY:Grand Round Webinar: Research 101: What data can I report from my TMS practice\, and how can I report it?
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Research 101: What data can I report from my TMS practice\, and how can I report it?"\nSpeaker: Andrew F. Leuchter\, MD\nrTMS is a rapidly growing area of clinical practice. Many practitioners have created innovative approaches to treatment\, observed novel findings that could help improve outcomes\, or discovered new potential indications for rTMS treatment. This presentation will review the types of data that can be reported in the scientific and clinical literature\, how to approach creating a report\, and how to find the right "home" for publication. \nKey learning objectives include:\n\nPresent goals of naturalistic research in TMS practice.\nDiscuss different types of research report formats.\nConsider what constitutes a meaningful contribution to the literature.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language\n \n*Registered attendees will receive access to the on-demand video recording by Friday\, May 9\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen:\nUSA - May 6\, 2025 at 8:00pm ET | 5:00pm PT\nUK- May 7\, 2025 at 1:00am BST\nAustralia- May 7\, 2025 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \nAll Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event. \n> >Register Now <<\nAbout the Speaker: Andrew F. Leuchter\, MD\nAndrew F. Leuchter\, MD\, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders\, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of\nthe largest academic TMS program in the country and treats patients with depression\, OCD\, pain\, tinnitus\, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients. \nDr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression\, EEG biomarkers to guide treatment of neuropsychiatric illness\, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods\, and received the 2019 Outstanding Research Mentor Award from the Semel Institute. \nAndrew F. Leuchter\, MD\, is a Distinguished Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior\, and Director of the Neuromodulation Division at the Semel Institute. An expert on the treatment of mood disorders\, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS programs\, performing clinical treatment and translational research across campuses throughout Los Angeles. The dual mission of the Division is to provide care for patients with depression\, chronic pain\, OCD\, tinnitus\, and other difficult-to-treat neuropsychiatric illness\, as well as enhancing treatment effectiveness\, as well as clinical trials to improve treatment of depression\, Post-Traumatic Stress Disorder (PTSD)\, and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and uses brain-imaging techniques\, such as quantitative electroencephalography (qEEG) and magnetic resonance imaging (MRI) to examine brain function and predict which treatments are most likely to benefit individual patients. \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/grand-round-webinar-research-101-what-data-can-i-report-from-my-tms-practice-and-how-can-i-report-it/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/04/Events-Thumbnails.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250612T200000
DTEND;TZID=UTC:20250612T220000
DTSTAMP:20260412T152755
CREATED:20250311T204518Z
LAST-MODIFIED:20250311T204920Z
UID:2162-1749758400-1749765600@clinicaltmssociety.org
SUMMARY:FACTMS: Future Directions in TMS Therapy
DESCRIPTION:Future Directions in TMS Therapy\n📅 June 12\, 2025\n🕗 8:00 – 10:00 PM PT\n📍 Sheraton San Diego Hotel & Marina\, Marisol Room \n\n\n\n\n\n\n\n\n\n              \n\n\n\nDr. Siddiqi                                                                  Dr. Wiliams \n\n\n\n\n\n\n\n\n\nJoin FACTMS for a wonderful event during the Clinical TMS Society Annual Meeting.  The evening will feature the first Ad Astra Award presentation to Dr. Nolan Williams and Dr. Shan Siddiqi.  In addition to an inspiring presentation\, enjoy hors d’oeuvres\, specialty cocktails and a popular silent auction with vacation packages\, TMS memorabilia and other exciting items.   \n\n\n\n\n\n\n\n\nAll proceeds benefit the Bob Sammons Clinical TMS Research Grant. \nLEARN MORE >
URL:https://clinicaltmssociety.org/event/factms-future-directions-in-tms-therapy/
LOCATION:San Diego
CATEGORIES:Annual Meetings
ATTACH;FMTTYPE=image/webp:https://clinicaltmssociety.org/wp-content/uploads/2025/03/FACTMS-Banner-2.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250701T200000
DTEND;TZID=America/New_York:20250701T210000
DTSTAMP:20260412T152755
CREATED:20250605T223252Z
LAST-MODIFIED:20250610T211921Z
UID:2531-1751400000-1751403600@clinicaltmssociety.org
SUMMARY:Grand Rounds Webinar: Advocating for TMS Coverage: An International Perspective
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Advocating for TMS Coverage: An International Perspective\nSpeakers: Carlene MacMillan\, MD\, FCTMSS\, DFAACAP and Shelly Weiss Lahn\, BS\, CRA\nJoin leaders from the Clinical TMS Society for a global exploration of insurance coverage for Transcranial Magnetic Stimulation. This session will share insights from a survey of international CTMSS members\, expert interviews\, and a review of global reimbursement models. Learn how clinicians around the world are successfully advocating for broader TMS access—and gain practical strategies to advance coverage in your own region. \nKey learning objectives include: \n\nIdentify key differences in insurance coverage policies for TMS across international healthcare systems.\nAnalyze effective advocacy strategies used by clinicians and organizations to expand TMS access globally.\nApply insights from international case studies to develop tailored approaches for improving TMS coverage in participants' local contexts.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language \n*Registered attendees will receive access to the on-demand video recording by Monday\, July 7\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - July 1\, 2025 at 8:00pm ET | 5:00pm PT\nUK- July 2\, 2025 at 1:00am BST\nAustralia- July 2\, 2025 at 10:00am AEST \nCost:  \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speakers \nCarlene MacMillan MD\, FCTMSS\, DFAACAP\nDr. Carlene MacMillan is the co-chair of the Clinical TMS Society Insurance Committee and the Member-at-Large on the Executive Committee. She is also on the board of the Foundation for the Advancement of Clinical TMS. She is board-certified in adult and child psychiatry. Dr.MacMillan is the Chief Product Officer at Radial\, a network of interventional practices. \n  \n  \n  \nShelly Weiss Lahn BS\, CRA\nShelly Weiss Lahn is the co-chair of the Clinical TMS Society Insurance Committee. She is the CEO of Neuro Wellness TMS Centers of America in Coral Springs\, Florida and the owner of Overseas Referral Network of America\, an International Medical Concierge Service.
URL:https://clinicaltmssociety.org/event/grand-round-webinar-advocating-for-tms-coverage-an-international-perspective/
LOCATION:Zoom
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/06/advocacy-grand-rounds-featured.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250805T200000
DTEND;TZID=UTC:20250805T210000
DTSTAMP:20260412T152755
CREATED:20250708T165625Z
LAST-MODIFIED:20250806T205433Z
UID:2932-1754424000-1754427600@clinicaltmssociety.org
SUMMARY:Neuroimaging to Enhance Precision in Clinical Trials
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuroimaging to Enhance Precision in Clinical Trials\nSpeaker: Aristotle Voineskos\, MD\, PhD\, FRCPC\nThis Grand Rounds explores how the upcoming use of neuroimaging is being used to better direct clinical care. This session discusses precision medicine\, implementation strategies\, and learning health systems to deliver more targeted\, evidence-based treatments. The content is grounded in high-impact\, peer reviewed literature to ensure scientific rigor. \nKey learning objectives include: \n\nDesign considerations for imaging in trials.\nConsiderations for precision imaging in trials.\nEmerging applications of precision imaging in trials.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language \n*Registered attendees will receive access to the on-demand video recording by Monday\, August 11\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - August 5\, 2025 at 8:00pm ET | 5:00pm PT\nUK- August 6\, 2025 at 1:00am BST\nAustralia- August 6\, 2025 at 10:00am AEST \nCost:\nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \nAristotle Voineskos\, MD\, PhD\, FRCPC\nDr. Aristotle Voineskos is the Senior Vice President\, Research and Science & Director of the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH). At both CAMH and the University Health Network (UHN)\, he serves as the joint Vice President for the CAMH-UHN Partnership. Dr. Voineskos earned his MD and PhD at the University of Toronto\, and completed a research fellowship at Brigham and Women’s Hospital\, Harvard Medical School. Dr. Voineskos is a Professor of Psychiatry at the\nTemerty Faculty of Medicine. He is an internationally recognized researcher\, physician\, and leader\, who has been dedicated to helping people suffering from severe mental illness and brain disorders. \nDr. Voineskos has served in progressive clinical and research leadership roles across his career. In these roles\, he has significantly improved access to care\, reduced wait times\, and implemented and scaled evidence-based care models across the health system. Most recently as Vice President Research at CAMH\, he helped grow the research enterprise substantially\, via key pillars of equity\, training and evaluation\, clinical-research integration\, open science\, digital transformation\, and sustainability. He is known for driving innovation and enhancing team performance. As joint Vice President of the CAMH-UHN Partnership\, he helps lead the work across executive teams to deliver comprehensive physical and mental health care for patients\, and accelerate advancements in brain health sciences. \nDr. Voineskos has published over 300 papers many of which are in the leading journals of psychiatry\, neurology\, medicine\, and neuroscience. He has won numerous awards for his research and mentorship including the A.E. Bennett Award for Clinical/Translational Research from the Society of Biological Psychiatry (SOBP) in 2022 and the Joel Elkes Research Award from the American College of Neuropsychopharmacology (ACNP) in 2024.
URL:https://clinicaltmssociety.org/event/advocating-for-tms-coverage-an-international-perspective/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/07/Events-Featured-Images-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250902T200000
DTEND;TZID=UTC:20250902T210000
DTSTAMP:20260412T152755
CREATED:20250806T202527Z
LAST-MODIFIED:20250808T125813Z
UID:3024-1756843200-1756846800@clinicaltmssociety.org
SUMMARY:TMS for Stroke Rehabilitation
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: TMS for Stroke Rehabilitation\nSpeaker: Dylan J. Edwards\, PhD\nThe first demonstration of transcranial magnetic stimulation (TMS) occurred nearly 40 years ago\, and it showed that TMS could readily activate the human cortex without sophisticated targeting. However\, as a tool to probe and modify cortical function\, TMS has historically been limited by imprecise targeting. With new advances\, including neuronavigation and contemporary modeling of cortical electric field distribution\, we are now able to use TMS to examine the detailed functional organization of the primary motor cortex\, as well as how the cortex is reorganized after the brain is lesioned. In research to date\, patient responses to TMS have been variable\, and inaccurate targeting may be a key factor contributing to the high variability in response rate to repetitive TMS (rTMS) interventions. The precision of TMS targeting will be discussed in the context of neurorehabilitation and motor recovery. \nKey learning objectives include:\n\nDescribe the rationale for using TMS in recovery of motor function after damage to the cortico-spinal tract such as in stroke or spinal cord injury.\nDescribe the benefit of electric field modeling in estimating optimal treatment intensity.\nState the principal result of at least one rTMS/neurorecovery RCT over the past decade.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language \n*Registered attendees will receive access to the on-demand video recording by Friday\, September 8\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - September 2\, 2025 at 8:00pm ET | 5:00pm PT\nUK- September 3\, 2025 at 1:00am BST\nAustralia- September 3\, 2025 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nDylan J. Edwards\, PhD\nDr. Dylan J. Edwards is the Nancy Wachtel Shrier Director of Jefferson Moss Rehabilitation Research Institute\, Director of the Human Motor Recovery Laboratory at the Institute\, Professor in the Department of Rehabilitation Medicine at The Sidney Kimmel Medical College at Thomas Jefferson University\, and Adjunct Professor of Neuroscience and Director of the NeuroRehabilitation and Robotics Laboratory at Edith Cowan University. He is dedicated to translating basic science findings in neurologically healthy people to develop and evaluate novel\, clinically-relevant approaches for neurological assessment and neurorehabilitation in stroke and spinal cord injury using non-invasive stimulation\, neuromodulation\, robotics\, combinatorial therapies\, neuroimaging\, and telerehabilitation.
URL:https://clinicaltmssociety.org/event/tms-for-stroke-rehabilitation/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/08/Events-Featured-Images-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250926
DTEND;VALUE=DATE:20250929
DTSTAMP:20260412T152755
CREATED:20250625T220103Z
LAST-MODIFIED:20250930T182402Z
UID:2812-1758844800-1759103999@clinicaltmssociety.org
SUMMARY:PULSES
DESCRIPTION:This in-depth training course offers a certificate of completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers and some special guests.  Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best evidence. \nThe program includes: \n\nAn introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker\, who designed the first-ever TMS machine in 1985;\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies;\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management;\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, maintenance treatment;\nA lecture on TMS risks and their prevention and management\, including seizure protocol review;\nHands-on training on targeting\, coil placement\, and motor threshold determination with multiple TMS devices;\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain; and\nA special track with lectures and hands-on training tailed for TMS technicians; and\nAn extended Q & A Panel with all PULSES faculty and special guests.\n\nAfter completion of the course\, the clinician will have obtained a historical\, current\, and practical knowledge of the scientific basis for treating psychiatric patients with TMS. Technicians will have additional skills needed for daily patient assessment\, monitoring\, and administration of stimulation.\nAttendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion. \nDate/Time: 26-28 September 2025 | 9:00 am to 6:00 pm (PT) (time is subject to change) \nLocation: Providence\, Rhode island | Butler Hospital  |  345 Blackstone Blvd\, Providence\, RI 02906 \nCLICK HERE FOR MORE INFORMATION\n 
URL:https://clinicaltmssociety.org/event/pulses/
CATEGORIES:PULSES
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/06/26-28-September-2025.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251007T200000
DTEND;TZID=UTC:20251007T210000
DTSTAMP:20260412T152755
CREATED:20250903T132214Z
LAST-MODIFIED:20250903T154639Z
UID:3073-1759867200-1759870800@clinicaltmssociety.org
SUMMARY:The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings\, Lessons Learned\, Future Directions
DESCRIPTION:> >Register Now <<\nSpeaker: Scott T. Aaronson\, MD\nThe RECOVER study is a large randomized sham controlled study of vagus nerve stimulation in markedly treatment resistant depression involving 1000 participants. The first papers for the unipolar cohort have been published and submitted to the Centers for Medicare and Medicaid for re-consideration for coverage. This presentation will review the extensive database\, the important lessons learned about studying severely treatment resistant depression and anticipate possible future availability of this novel therapy. \nKey learning objectives include:\n\nIdentify how to improve assessment of patient outcomes in severely treatment resistant depression.\nRecognize patient presentations with increased likelihood of benefit from vagus nerve stimulation.\nDescribe the proposed mechanism of action for vagus nerve stimulation in treating depression.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne CME credit is available.  CE Language \n*Registered attendees will receive access to the on-demand video recording by Friday\, October 10\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - October 7\, 2025 at 8:00pm ET | 5:00pm PT\nUK- October 8\, 2025 at 1:00am BST\nAustralia- October 8\, 2025 at 10:00am AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nScott T. Aaronson\, MD\nDr. Scott Aaronson is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine\, distinguished life fellow of the American Psychiatric Association\, and is a fellow of the American College of Psychiatrists\, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr. Aaronson also serves on the board of the American Society for Clinical Psychopharmacology. He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital.\nDr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders\, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS)\, Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. His paper on a five year observational study of VNS in treatment resistant depression published in 2017 in the American Journal of Psychiatry led to the Centers for Medicare and Medicaid supporting a randomized clinical trial of VNS in unipolar and bipolar depression through their Coverage with Evidence Development Program. He is on the committee that developed this study and is now in the process of publishing the results from the unipolar arm in a series of articles.
URL:https://clinicaltmssociety.org/event/the-recover-trial-of-vagus-nerve-stimulation-in-markedly-treatment-resistant-depression-critical-findings-lessons-learned-future-directions/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2025/09/Events-Featured-Images-3.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251202T200000
DTEND;TZID=UTC:20251202T210000
DTSTAMP:20260412T152755
CREATED:20251030T165119Z
LAST-MODIFIED:20251114T153619Z
UID:3226-1764705600-1764709200@clinicaltmssociety.org
SUMMARY:First Principles of TMS Induced Synaptic Plasticity and Potential Impact on Clinical Outcomes
DESCRIPTION:> >Register Now <<\nSpeaker: Alex McGirr\, MD\, PhD\, FRCPC\nTranscranial magnetic stimulation is delivered in patterns of pulses that are informed by pre-clinical electrophysiology to induce changes at the level of the synapse. Our delivery of this treatment is agnostic to two major confounds that influence the ability of synaptic weights to change in response to stimulation:\na) disease processes limiting plasticity\nb) concurrent pharmacology\nThis grand rounds will review clinically relevant implications of these\, and the emerging space using pharmacological adjuvants to enhance the effects of stimulation and its relation to clinical outcomes. \nKey learning objectives include:\n\nExplain the mechanisms of transcranial magnetic stimulation (TMS)\, inclucing how pulse patterns influence synaptic plasticity and the role of electrophysiological principles.\nIdentify factors that affect synaptic responsiveness to TMS\, such as disease-related limitations in plasticity and the impact of concurrent pharmacological treatments.\nDiscuss the clinical implications of combining TMS with pharmacological adjuvants\, including how these interactions can enhance stimulation effects and influence clinical outcomes.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, December 5\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - December 2\, 2025 at 8:00pm ET | 5:00pm PT\nUK- December 3\, 2025 at 1:00am GMT\nAustralia- December 3\, 2025 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nAlexander McGirr\, MD\, PhD\, FRCPC\nDr. Alexander McGirr is a psychiatrist and clinician scientist at the University of Calgary\, Canada. He trained across major Canadian institutions\, including\nMcGill University (undergraduate and masters of neuroscience)\, the University of Toronto (MD)\, and the University of British Columbia (psychiatry residency\nand PhD neuroscience). His clinical work and research focuses on mood disorders\, circuit dissection\, and non-invasive neurostimulation as both a means\nof probing the brain and inducing changes in neural circuits underlying pathology. Although his research program includes both basic science and\nclinical arms\, the focus of this ground rounds will be clinical.
URL:https://clinicaltmssociety.org/event/first-principles-of-tms-induced-synaptic-plasticity-and-potential-impact-on-clinical-outcomes/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/10/Events-Featured-Images-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260106T200000
DTEND;TZID=UTC:20260106T210000
DTSTAMP:20260412T152755
CREATED:20251203T171225Z
LAST-MODIFIED:20251211T164857Z
UID:3445-1767729600-1767733200@clinicaltmssociety.org
SUMMARY:Single-Day Regimens for TMS: Recent Progress and Open Questions *Free Session*
DESCRIPTION:Kick off the year with complimentary Grand Rounds!\n> >Register Now <<\nSpeaker: Jonathan Downar\, MD\, PhD\, FRCPC\nImproving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients\, especially those in remote areas. \nRecently\, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols\, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality\, tolerability\, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment. \nKey learning objectives include:\n\nReview rationale\, mechanisms\, and history of development of single-day TMS protocols.\nReview recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.\nReview outstanding questions facing future developments and refinement of single-day TMS protocols.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, January 9\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - January 6\, 2026 at 8:00pm ET | 5:00pm PT\nUK- January 7\, 2026 at 1:00am GMT\nAustralia- January 7\, 2026 at 12:00pm AEDT \nCost: \nMember: FREE\nTrainee Member: FREE\nNon-Member: FREE \n*CME not available for this session. \n> >Register Now <<\nAbout the Speaker \n \nJonathan Downar\, MD\, PhD\, FRCPC \nDr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto\, trained in medicine at the University of Calgary\, and completed his psychiatry residency at the University of Toronto. \nDr Downar has published over 180 peer-reviewed articles on TMS and brain imaging\, in journals including Lancet\, JAMA Psychiatry\, Nature Medicine\, Nature Neuroscience\, and Brain Stimulation. He is the senior author of the THREE-D study\, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders. \nHe is currently working to develop novel protocols that improve the practicality and economics of TMS\, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.
URL:https://clinicaltmssociety.org/event/single-day-regimens-for-tms-recent-progress-and-open-questions/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/12/Events-Featured-Images.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Dubai:20260203T200000
DTEND;TZID=Asia/Dubai:20260203T210000
DTSTAMP:20260412T152755
CREATED:20260107T174232Z
LAST-MODIFIED:20260107T174232Z
UID:3559-1770148800-1770152400@clinicaltmssociety.org
SUMMARY:TMS for Schizophrenia
DESCRIPTION:> >Register Now <<\nSpeaker: Roscoe Brady\, PhD\, MD\nIn this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations\, negative symptoms\, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally\, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity. \nKey learning objectives include:\n\nSummarize the history of TMS trials for medication resistant symptoms of schizophrenia.\nDescribe how TMS is used as a research tool for understanding schizophrenia pathology.\nDescribe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, February 6\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - February 3\, 2026 at 8:00pm ET | 5:00pm PT\nUK- February 4\, 2026 at 1:00am GMT\nAustralia- February 4\, 2026 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nRoscoe Brady\nRoscoe Brady MD\, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.
URL:https://clinicaltmssociety.org/event/tms-for-schizophrenia/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/01/Events-Featured-Images1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260303T200000
DTEND;TZID=UTC:20260303T210000
DTSTAMP:20260412T152755
CREATED:20260204T154404Z
LAST-MODIFIED:20260204T154526Z
UID:3684-1772568000-1772571600@clinicaltmssociety.org
SUMMARY:Accelerated TMS for Depression: Does Imaging Matter?
DESCRIPTION:> >Register Now <<\nSpeaker: Joseph J. Taylor\, MD\, PhD\nNeuroimaging is common in psychiatric research but rarely applied in psychiatric practice\, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently\, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)\, this intervention resulted in rapid and substantial antidepressant benefits. However\, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here\, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression. \nKey learning objectives include:\n\nDescribe the development of accelerated TMS.\nOutline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.\nSummarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, March 6\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - March 3\, 2026 at 8:00pm ET | 5:00pm PT\nUK- March 4\, 2026 at 1:00am GMT\nAustralia- March 4\, 2026 at 12:00pm AEDT \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nJoseph J. Taylor\, MD\, PhD\nDr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital\, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics\, the Director of the Interventional Psychiatry Research Program\, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry\, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career\, Dr. Taylor has received funding from the Howard Hughes Medical Institute\, the National institutes of Health\, the Sidney R. Baer\, Jr. Foundation\, the Baszucki Group\, the Brain and Behavioral Research Foundation\, Mass General Brigham\, and Harvard Medical School.
URL:https://clinicaltmssociety.org/event/accelerated-tms-for-depression-does-imaging-matter/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/02/March-2026-GR-Thumb.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260307
DTEND;VALUE=DATE:20260309
DTSTAMP:20260412T152755
CREATED:20251029T214834Z
LAST-MODIFIED:20251205T204826Z
UID:3219-1772841600-1773014399@clinicaltmssociety.org
SUMMARY:CTMSS Training Singapore:  PULSES & Pain Academy
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/ctmss-training-singapore-pulses-pain-academy/
CATEGORIES:PULSES
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260407T200000
DTEND;TZID=UTC:20260407T210000
DTSTAMP:20260412T152755
CREATED:20260304T162017Z
LAST-MODIFIED:20260304T162017Z
UID:3928-1775592000-1775595600@clinicaltmssociety.org
SUMMARY:Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
DESCRIPTION:> >Register Now <<\nSpeaker: Lindsay Oberman\, PhD\nThis talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally\, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS. \nKey learning objectives include:\n\nGain awareness of what indications are "on label" versus "off label."\nGain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.\nGain understanding of ethical considerations regarding marketing and use of rTMS off-label.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, April 10\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - April 7\, 2026 at 8:00pm ET | 5:00pm PT\nUK- April 8\, 2026 at 1:00am BST\nAustralia- April 8\, 2026 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nLindsay Oberman\, PhD\nDr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time\, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism\, mood disorders\, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation\, sensory processing\, social cognition\, and executive functioning across disorders. In doing so\, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.
URL:https://clinicaltmssociety.org/event/marketing-promotion-of-off-label-uses-of-repetitive-tms-treatment-rtms/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/03/April-2026-GR.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260505T200000
DTEND;TZID=UTC:20260505T210000
DTSTAMP:20260412T152755
CREATED:20260408T163027Z
LAST-MODIFIED:20260408T163027Z
UID:4127-1778011200-1778014800@clinicaltmssociety.org
SUMMARY:Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
DESCRIPTION:> >Register Now <<\nSpeaker: Linda Carpenter\, MD\nEarlier this year\, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription\, Proliv™Rx is a wearable\, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes. \nDr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice. \nKey learning objectives include:\n\nEvaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).\nDescribe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.\nDiscuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.\n\nOne CME credit is available.  CE Language \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, May 8\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - May 5\, 2026 at 8:00pm ET | 5:00pm PT\nUK- May 6\, 2026 at 1:00am BST\nAustralia- May 6\, 2026 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nLinda Carpenter\, MD\nDr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials\, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders. \nFor the past two decades\, Dr. Carpenter's primary research focus has included therapeutic brain stimulation\, and she has led numerous studies examining the efficacy\, safety\, and mechanisms of VNS\, DBS\, tDCS\, TMS\, and other neuromodulation devices in clinical populations. \nDr. Carpenter recently led the multi-center investigation of Proliv\, a novel\, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression\, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit. \nFor the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment. \nDr. Carpenter is the current Director of the CTMSS’s PULSES training course\, and she serves on multiple other CTMSS committees. \n 
URL:https://clinicaltmssociety.org/event/combined-occipital-and-trigeminal-afferent-stimulation-for-depression-findings-from-the-randomized-controlled-trial-and-the-new-proliv-home-use-neuromodulation-device/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/04/Events-Featured-Images2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260603
DTEND;VALUE=DATE:20260605
DTSTAMP:20260412T152755
CREATED:20251205T202828Z
LAST-MODIFIED:20251205T204613Z
UID:3474-1780444800-1780617599@clinicaltmssociety.org
SUMMARY:PULSES Boston
DESCRIPTION:Course Overview\nThis in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers\, along with special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best available evidence. \nThe Program Includes:\n\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies.\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management.\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, and maintenance treatment.\nA revised lecture on TMS risks and their prevention and management\, including seizure protocol review.\nHands-on training on coil location placement & motor threshold determination with multiple TMS devices.\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain.\nAn extended Q&A Panel with all PULSES faculty and special guests.\n\nMORE DETAILS COMING SOON...  Sign up for updates on when CTMSS opens PULSES registration...
URL:https://clinicaltmssociety.org/event/pulses-boston/
CATEGORIES:PULSES
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260604
DTEND;VALUE=DATE:20260605
DTSTAMP:20260412T152755
CREATED:20251230T150807Z
LAST-MODIFIED:20251230T150807Z
UID:3548-1780531200-1780617599@clinicaltmssociety.org
SUMMARY:Pain Academy Boston
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/pain-academy-boston/
CATEGORIES:Pain Academy
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260604
DTEND;VALUE=DATE:20260607
DTSTAMP:20260412T152755
CREATED:20251015T221100Z
LAST-MODIFIED:20251015T221100Z
UID:3190-1780531200-1780790399@clinicaltmssociety.org
SUMMARY:CTMSS 14th Annual Meeting
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/ctmss-14th-annual-meeting/
CATEGORIES:Annual Meetings
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/10/CTMSS-2026-Banner-Options-600-x-338-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261026
DTSTAMP:20260412T152755
CREATED:20251205T204708Z
LAST-MODIFIED:20251205T204708Z
UID:3499-1792713600-1792972799@clinicaltmssociety.org
SUMMARY:PULSES Providence
DESCRIPTION:Course Overview\nThis in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers\, along with special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best available evidence. \nThe Program Includes:\n\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies.\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management.\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, and maintenance treatment.\nA revised lecture on TMS risks and their prevention and management\, including seizure protocol review.\nHands-on training on coil location placement & motor threshold determination with multiple TMS devices.\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain.\nAn extended Q&A Panel with all PULSES faculty and special guests.\n\nMORE DETAILS COMING SOON...  Sign up for updates on when CTMSS opens PULSES registration...
URL:https://clinicaltmssociety.org/event/pulses-providence/
CATEGORIES:PULSES
END:VEVENT
END:VCALENDAR